Fused-Ring Piperidine 5-HT2A Modulator for Rapid Antidepressant Action
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antidepressants, such as SSRIs and ketamine, have slow onset of action, low response rates, and adverse effects like nausea and hallucinations, while psychedelics and lumateperone lack clarity in mechanism and are limited to specific disorders.
Innovation Solution
Development of a fused-piperidine compound that acts as a 5-HT 2A receptor modulator, avoiding hallucinogenic side effects and providing rapid antidepressant effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If SSRIs are used to treat depression, then tolerance and safety are improved, but onset of action is slow and adverse reactions occur
Solution Approach 1:
The patent modifies the molecular structure of lumateperone by changing chemical parameters (introducing specific substituents at defined positions) to create a new compound with improved pharmacological properties, achieving rapid onset while maintaining safety profile
2Loss of time
If ketamine is used to treat depression, then rapid antidepressant effect is achieved, but hallucinogenic side effects and addiction risks occur
Solution Approach 1:
The patent introduces specific local structural features (substituents at particular positions in the molecular structure) to selectively modulate receptor binding properties, achieving rapid antidepressant effect through 5-HT2A receptor modulation while avoiding hallucinogenic effects by controlling local chemical properties
Solution Approach 2:
The patent changes key molecular parameters (substituent types, positions, and configurations) to optimize the compound's interaction with neuronal receptors, producing rapid antidepressant efficacy without the harmful hallucinogenic side effects associated with ketamine
3Loss of information
If lumateperone is used to treat depression, then mechanism of action is clarified through 5-HT2A receptor antagonism, but response rate is limited to 51.1% and applicability is restricted to bipolar depression
Solution Approach 1:
The patent creates a compound structure that can broadly activate multiple relevant neurotransmitter systems (5-HT2A, D2, SERT modulation) to provide universal antidepressant efficacy across different depression types including major depression, treatment-resistant depression, and bipolar depression
Solution Approach 2:
The patent optimizes molecular parameters to enhance the compound's ability to modulate multiple receptor systems simultaneously, improving response rate and expanding applicability to various depression subtypes while maintaining clear mechanism of action through controlled receptor interactions
Data Source
Figure 1~2
Figure 3
Figure 4~5
AI summary
Disclosed are a fused ring piperidine compound, and a preparation method therefor and the use thereof. The fused ring piperidine compound is as represented by formula I'. The fused ring piperidine compound has a relatively good anti-depression effect, and has good application prospects.